Drug Manufacturers - Specialty & Generic industry analysis: EL7 Score and the best stocks ranked by value, profitability, and momentum.
89 of 152
P/E 17.9 vs period average 18.0 Near its historical average
Ranked among 28 stocks with a market cap above $500M. Smaller companies are excluded from the ranking.
Rank | Company | Price | P/E | Value | Growth | Quality | EL7 Score |
|---|---|---|---|---|---|---|---|
| 1/28 | ![]() | $10.10 | 12.1 | 82 | 97 | 95 | 100 |
| 2/28 | ![]() | $71.05 | 15.7 | 85 | 95 | 85 | 96 |
| 3/28 | ![]() | $36.39 | 101.1 | 56 | 60 | 89 | 92 |
| 4/28 | ![]() | $100.11 | 23.9 | 33 | 52 | 91 | 89 |
| 5/28 | ![]() | $34.46 | 12.4 | 74 | 81 | 72 | 88 |
| 6/28 | ![]() | $25.53 | 15.1 | 85 | 52 | 77 | 86 |
| 7/28 | ![]() | $20.29 | 55.5 | 49 | 68 | 74 | 82 |
| 8/28 | ![]() | $6.25 | — | 95 | 27 | 86 | 82 |
| 9/28 | ![]() | $78.80 | 13.3 | 75 | 55 | 90 | 77 |
| 10/28 | ![]() | $44.35 | 116.9 | 15 | 53 | 92 | 75 |
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Insider purchases in the sector's stocks
Funds that track the sector and each fund's exposure to it.
Fund | Exposure | Assets | Expense |
|---|---|---|---|
| IBBiShares Biotechnology ETF | 100.0% | $11B | 0.44% |
| VHTVanguard Health Care ETF | 100.0% | $22B | 0.09% |
| IHIiShares U.S. Medical Devices ETF | 99.7% | $4B | 0.37% |
| XLVState Street Health Care Select Sector SPDR ETF | 99.1% | $47B | 0.08% |
The percentage is the sector's share of the fund's assets, per the latest available data.
Upgrades and downgrades on the sector's stocks